The primary antibodies employed were: P53 (Proteintech, 60283-2-Ig), pSer46-P53 (CST, 2521), FOXO4 (Proteintech, 21535-1-AP), P21 (CST, 2947), P16 (CST, 18769), BAX (CST, 2772), BCL2 (CST, 3498), Ki-67 (Proteintech, 84192-4-RR), Lamin B (CST, 13435), Cleaved Caspase 3 (CST, 9664), -H2AX (Abcam, ab81299), and GAPDH (Abcam, ab8245) as an internal reference for normalizing protein expression levels
It takes 30 seconds and prevents the most common denial category
Risk 5: Loss of Appetite Regulation Poor absorption = unstable appetite control and inconsistent metabolic response
Intravenous therapies are medical treatments that must be evaluated and administered by a licensed provider after an in-person assessment
However, it's crucial to inform our medical team about all medications and supplements you're taking to avoid potential interactions